Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia
Abstract Schizophrenia (SZ) is a deleterious brain disorder characterised by its heterogeneity and complex symptomatology consisting of positive, negative and cognitive deficits. Current antipsychotic drugs ameliorate the positive symptomatology, but are inefficient in treating the negative symptoma...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-01-01
|
| Series: | Translational Psychiatry |
| Online Access: | https://doi.org/10.1038/s41398-024-03194-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594413777321984 |
|---|---|
| author | David Olivares-Berjaga Albert Martínez-Pinteño Natalia Rodríguez Sergi Mas Constanza Morén Eduard Parellada Patricia Gassó |
| author_facet | David Olivares-Berjaga Albert Martínez-Pinteño Natalia Rodríguez Sergi Mas Constanza Morén Eduard Parellada Patricia Gassó |
| author_sort | David Olivares-Berjaga |
| collection | DOAJ |
| description | Abstract Schizophrenia (SZ) is a deleterious brain disorder characterised by its heterogeneity and complex symptomatology consisting of positive, negative and cognitive deficits. Current antipsychotic drugs ameliorate the positive symptomatology, but are inefficient in treating the negative symptomatology and cognitive deficits. The neurodevelopmental glutamate hypothesis of SZ has opened new avenues in the development of drugs targeting the glutamatergic system. One of these new therapies involves the positive allosteric modulators (PAMs) of metabotropic glutamate receptors, mainly types 2/3 (mGluR2/3). mGluR2/3 PAMs are selective for the receptor, present high tolerability and can modulate the activity of the receptor for long periods. There is not much research in clinical trials regarding mGluR2/3 PAMs. However, several lines of evidence from animal models have indicated the efficiency of mGluR2/3 PAMs. In this review, focusing on in vivo animal studies, we will specifically discuss the utilization of SZ animal models and the various methods employed to assess animal behaviour before summarising the evidence obtained to date in the field of mGluR2/3 PAMs. By doing so, we aim to deepen our understanding of the underlying mechanisms and the potential efficiency of mGluR2/3 PAMs in treating SZ. Overall, mGluR2/3 PAMs have demonstrated efficiency in attenuating SZ-like behavioural and molecular deficits in animal models and could be useful for the early management of the disorder or to treat specific subsets of patients. |
| format | Article |
| id | doaj-art-700f4d0d32494281ba829a18ded9f05c |
| institution | Kabale University |
| issn | 2158-3188 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Translational Psychiatry |
| spelling | doaj-art-700f4d0d32494281ba829a18ded9f05c2025-01-19T12:39:40ZengNature Publishing GroupTranslational Psychiatry2158-31882025-01-0115111410.1038/s41398-024-03194-2Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophreniaDavid Olivares-Berjaga0Albert Martínez-Pinteño1Natalia Rodríguez2Sergi Mas3Constanza Morén4Eduard Parellada5Patricia Gassó6Department of Basic Clinical Practice, University of BarcelonaDepartment of Basic Clinical Practice, University of BarcelonaDepartment of Basic Clinical Practice, University of BarcelonaDepartment of Basic Clinical Practice, University of BarcelonaInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)Department of Basic Clinical Practice, University of BarcelonaAbstract Schizophrenia (SZ) is a deleterious brain disorder characterised by its heterogeneity and complex symptomatology consisting of positive, negative and cognitive deficits. Current antipsychotic drugs ameliorate the positive symptomatology, but are inefficient in treating the negative symptomatology and cognitive deficits. The neurodevelopmental glutamate hypothesis of SZ has opened new avenues in the development of drugs targeting the glutamatergic system. One of these new therapies involves the positive allosteric modulators (PAMs) of metabotropic glutamate receptors, mainly types 2/3 (mGluR2/3). mGluR2/3 PAMs are selective for the receptor, present high tolerability and can modulate the activity of the receptor for long periods. There is not much research in clinical trials regarding mGluR2/3 PAMs. However, several lines of evidence from animal models have indicated the efficiency of mGluR2/3 PAMs. In this review, focusing on in vivo animal studies, we will specifically discuss the utilization of SZ animal models and the various methods employed to assess animal behaviour before summarising the evidence obtained to date in the field of mGluR2/3 PAMs. By doing so, we aim to deepen our understanding of the underlying mechanisms and the potential efficiency of mGluR2/3 PAMs in treating SZ. Overall, mGluR2/3 PAMs have demonstrated efficiency in attenuating SZ-like behavioural and molecular deficits in animal models and could be useful for the early management of the disorder or to treat specific subsets of patients.https://doi.org/10.1038/s41398-024-03194-2 |
| spellingShingle | David Olivares-Berjaga Albert Martínez-Pinteño Natalia Rodríguez Sergi Mas Constanza Morén Eduard Parellada Patricia Gassó Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia Translational Psychiatry |
| title | Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia |
| title_full | Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia |
| title_fullStr | Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia |
| title_full_unstemmed | Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia |
| title_short | Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia |
| title_sort | effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2 3 mglur2 3 in animal models of schizophrenia |
| url | https://doi.org/10.1038/s41398-024-03194-2 |
| work_keys_str_mv | AT davidolivaresberjaga effectivenessofpositiveallostericmodulatorsofmetabotropicglutamatereceptor23mglur23inanimalmodelsofschizophrenia AT albertmartinezpinteno effectivenessofpositiveallostericmodulatorsofmetabotropicglutamatereceptor23mglur23inanimalmodelsofschizophrenia AT nataliarodriguez effectivenessofpositiveallostericmodulatorsofmetabotropicglutamatereceptor23mglur23inanimalmodelsofschizophrenia AT sergimas effectivenessofpositiveallostericmodulatorsofmetabotropicglutamatereceptor23mglur23inanimalmodelsofschizophrenia AT constanzamoren effectivenessofpositiveallostericmodulatorsofmetabotropicglutamatereceptor23mglur23inanimalmodelsofschizophrenia AT eduardparellada effectivenessofpositiveallostericmodulatorsofmetabotropicglutamatereceptor23mglur23inanimalmodelsofschizophrenia AT patriciagasso effectivenessofpositiveallostericmodulatorsofmetabotropicglutamatereceptor23mglur23inanimalmodelsofschizophrenia |